miR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting hedgehog/smoothened

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 6, 2015, Pages 6397-6406

  Zhang, Xiang Liang ^a   Shi, Hui Juan ^b   Wang, Ji Ping ^c   Tang, Hong Sheng ^a   Cui, Shu Zhong ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Gastric cancer; Hedgehog; Hsa miR 218; Multi drug resistance; SMO

Indexed keywords

G PROTEIN COUPLED RECEPTOR; MICRORNA; MIRN218 MICRORNA, HUMAN; SMO PROTEIN, HUMAN; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN;

BIOSYNTHESIS; DRUG RESISTANCE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; MULTIDRUG RESISTANCE; REAL TIME POLYMERASE CHAIN REACTION; STOMACH TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; SMOOTHENED RECEPTOR; STOMACH NEOPLASMS; TRANSFECTION;

EID: 84938566226     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Zhang XL, Shi HJ, Cui SZ, Tang YQ and Ba MC. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. Eur J Surg Oncol 2011; 37: 466-472.
3. Archie V, Kauh J, Jones DV Jr, Cruz V, Karpeh MS Jr and Thomas CR Jr. Gastric cancer: standards for the 21st century. Crit Rev Oncol Hematol 2006; 57: 123-131.
4. Zhang Y, Lu Q and Cai X. MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett 2013; 587: 3069-3075.
5. Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li K, Zhou L, Sun Y, Li M, Zhou J, An Y, Wu K, Nie Y and Fan D. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 2014; 33: 3267-3276.
6. Yan LH, Wang XT, Yang J, Kong FB, Lian C, Wei WY, Luo W, Xie YB and Xiao Q. Reversal of multidrug resistance in gastric cancer cells by E2F-1 downregulation in vitro and in vivo. J Cell Biochem 2014; 115: 34-41.
7. Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, Jiang B, Shu Y and Liu P. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012; 69: 723-731.
8. Falasca M and Linton KJ. Investigational ABC transporter inhibitors. Expert Opin Investig Drugs 2012; 21: 657-666.
9. Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, Comoglio PM and Giordano S. MicroRNAs impair MET-mediated invasive growth. Cancer Res 2008; 68: 10128-10136.
10. Chen Z, Ma T, Huang C, Zhang L, Lv X, Xu T, Hu T and Li J. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/beta-catenin pathway in hepatocellular carcinoma cells. Cell Signal 2013; 25: 2693-2701.
11. Takwi AA, Wang YM, Wu J, Michaelis M, Cinatl J and Chen T. miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells. Oncogene 2014; 33: 3717-3729.
12. Guan H, Wei G, Wu J, Fang D, Liao Z, Xiao H, Li M and Li Y. Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer. J Clin Endocrinol Metab 2013; 98: E1334-1344.
13. Liu Y, Yan W, Zhang W, Chen L, You G, Bao Z, Wang Y, Wang H, Kang C and Jiang T. MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. Oncol Rep 2012; 28: 1013-1021.
14. Tu Y, Gao X, Li G, Fu H, Cui D, Liu H, Jin W and Zhang Y. MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res 2013; 73: 6046-6055.
15. Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, Omura K and Inazawa J. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 2011; 71: 5765-5778.
16. Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, Li Q, Qiao T, Zhao Q, Nie Y and Fan D. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 2010; 6: e1000879.
17. Zhang XL, Shi HJ, Wang JP, Tang HS, Wu YB, Fang ZY, Cui SZ and Wang LT. MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin. World J Gastroenterol 2014; 20: 11347-11355.
18. Zhang XL, Hu AB, Cui SZ and Wei HB. Thermotherapy enhances oxaliplatin-induced cytotoxicity in human colon carcinoma cells. World J Gastroenterol 2012; 18: 646-653.
19. Liu C, Zhang F, Li T, Lu M, Wang L, Yue W and Zhang D. MirSNP, a database of polymorphisms altering miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs. BMC Genomics 2012; 13: 661.
20. Kumar A, Wong AK, Tizard ML, Moore RJ and Lefevre C. miRNA_Targets: a database for miRNA target predictions in coding and non-coding regions of mRNAs. Genomics 2012; 100: 352-356.
21. Hilgeroth A, Hemmer M and Coburger C. The impact of the induction of multidrug resistance transporters in therapies by used drugs: recent studies. Mini Rev Med Chem 2012; 12: 1127-1134.
22. Rodrigues AS, Dinis J, Gromicho M, Martins C, Laires A and Rueff J. Genomics and cancer drug resistance. Curr Pharm Biotechnol 2012; 13: 651-673.
23. Xia CQ and Smith PG. Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation. Mol Pharmacol 2012; 82: 1008-1021.
24. Lee CH. Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol 2010; 596: 325-340.
25. Palmeira A, Sousa E, Vasconcelos MH and Pinto MM. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 2012; 19: 1946-2025.
26. Chen Y and Jiang J. Decoding the phosphorylation code in Hedgehog signal transduction. Cell Res 2013; 23: 186-200.
27. Hadden MK. Hedgehog pathway inhibitors: a patent review (2009--present). Expert Opin Ther Pat 2013; 23: 345-361.
28. Robbins DJ, Fei DL and Riobo NA. The Hedgehog signal transduction network. Sci Signal 2012; 5: re6.
29. Marini KD, Payne BJ, Watkins DN and Martelotto LG. Mechanisms of Hedgehog signalling in cancer. Growth Factors 2011; 29: 221-234.
30. McMillan R and Matsui W. Molecular pathways: the hedgehog signaling pathway in cancer. Clin Cancer Res 2012; 18: 4883-4888.
31. Polizio AH, Chinchilla P, Chen X, Manning DR and Riobo NA. Sonic Hedgehog activates the GTPases Rac1 and RhoA in a Gli-independent manner through coupling of smoothened to Gi proteins. Sci Signal 2011; 4: pt7.
32. Queiroz KC, Spek CA and Peppelenbosch MP. Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors. Drug Resist Updat 2012; 15: 211-222.
33. Kiselyov AS. Targeting the hedgehog signaling pathway with small molecules. Anticancer Agents Med Chem 2006; 6: 445-449.
34. Kean S. Medicine. Disrupting Hedgehog may reverse advanced cancer, if only temporarily. Science 2009; 325: 1188.
35. Guo J, Gao J, Li Z, Gong Y, Man X, Jin J and Wu H. Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activation in vitro and in vivo. Cancer Lett 2013; 339: 185-194.